Feasibility Study of Pharmacist Led HTN Management Utilising Vitrucare
Research type
Research Study
Full title
A Feasibility Study of Pharmacist Led Hypertension Management Utilising the VitruCare Platform
IRAS ID
294225
Contact name
Paul Rutter
Contact email
Sponsor organisation
University of Portsmouth
Clinicaltrials.gov Identifier
NHE-11CA03-0013, UoP Insurance Reference
Duration of Study in the UK
0 years, 6 months, 0 days
Research summary
The use of software applications to help manage patient health has been steadily rising for many years and has further increased during the COVID pandemic. This study will investigate one such application called VitruCare. Vitrucare is a PC and mobile application that allows patients to access information to promote self-care and manage their particular health condition. It also allows patients to provide information to their healthcare professional about their condition and how it is being managed. This study specifically looks at people with high blood pressure and to see the feasibility and acceptability of using VitruCare as well as to determine if the use of Vitrucare has any effects on their perceptions and management of hypertension and their health.
Eligible patients with existing uncontrolled and newly diagnosed high blood pressure will be asked to be part of the study and recruited from one General Practice in West Yorkshire. The management of patients’ high blood pressure will be identical to normal care except for the addition of offering the use of VitruCare.
The study will investigate the feasibility and acceptability of VitruCare, including if (and how) it has impacted upon participants health and general wellbeing. This information will be gained through the analysis of participants' medical records held at the practice for the duration of the study, use of VitruCare analytics, completion of validated surveys assessing quality of life, and interviews with the participants.
REC name
London - Surrey Research Ethics Committee
REC reference
23/LO/0579
Date of REC Opinion
17 Aug 2023
REC opinion
Further Information Favourable Opinion